Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13450627 | 0.82 | HDAC6 (0.57) | MAPK14CYP2C9MAPK11EPHX2HDAC6 | |
| SCHEMBL5420230 | 0.82 | GABRA1 (0.60) | MAPK14CYP2C9MAPK11HDAC6GABRA5 | |
| SCHEMBL3409240 | 0.82 | L3MBTL1 (0.57) | MAPK14CYP2C9MAPK11HDAC6GABRA5 | |
| SCHEMBL29926296 | 0.79 | HDAC6 (0.59) | MAPK14CYP2C9HDAC6MLYCDHDAC4 | |
| SCHEMBL4007129 | 0.78 | L3MBTL1 (0.53) | MAPK14CYP2C9MAPK11HDAC6GABRA5 | |
| SCHEMBL14160465 | 0.78 | EPHX2 (0.46) | KDM1ARCOR1MAPK14CYP2C9MAPK11 | |
| SCHEMBL2863458 | 0.78 | TAS1R3 (0.53) | MAPK14HDAC6HDAC4 | |
| SCHEMBL1542860 | 0.77 | GABRA5 (0.59) | MAPK14CYP2C9MAPK11GABRA5 | |
| SCHEMBL4648730 | 0.77 | HDAC6 (0.58) | HDAC6MLYCDNAMPT | |
| SCHEMBL3404706 | 0.77 | HDAC6 (0.55) | HDAC6MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497351-B2 | 3-N-cyclopropylmethyl-2-fluorobenzamide compound, preparation method therefor and use thereof | CAC NANTONG CHEMICAL CO., LTD (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20230020373-A1 | 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CAC NANTONG CHEMICAL CO., LTD (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497351-B2 | 3-N-cyclopropylmethyl-2-fluorobenzamide compound, preparation method therefor and use thereof | CYP51A1, DDT, CYP4F11 | KDM1A 932/4885RCOR1 4050/4885MAPK14 1062/4885 |
| US-20230020373-A1 | 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, DDT, CYP4F11 | KDM1A 932/4885RCOR1 4050/4885MAPK14 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.